Opioid use accelerates neurocognitive impairment in HIV/AIDS patients. We assessed the effect of chronic morphine treatment and LP-BM5/murine AIDS (MAIDS) infection on cognition, cytokine production, and type 1 interferon (IFN) expression in the murine CNS. Morphine treatment decreased expression of pro-inflammatory factors (CCL5, iNOS) and reduced cognitive performance in LP-BM5-infected mice, correlating to increased hippocampal viral load and a blunted type 1 IFN response. In the striatum, morphine reduced viral load while increasing IFN-α RNA expression. Our results suggest that differentially regulated type 1 IFN responses may contribute to distinct regional outcomes in the hippocampus and striatum in LP-BM5/MAIDS.
Introduction
Nearly half of HIV-1-infected patients exhibit signs of HIV-associated neurocognitive deficits (HAND), despite improved viral control with modern combination antiretroviral therapy (Heaton et al., 2010; Robertson et al., 2007) . Heroin, morphine, and other opioids/opiates increase both the risk and severity of HAND (Hauser et al., 2012; Nath et al., 2002; Roy et al., 2011) . With nearly one-third of patients reporting opioid abuse, these drugs can significantly impact disease outcomes and quality of life for HIV patients (Bell et al., 1998; UNAIDS, 2013) .
Morphine interacts with neurotoxic HIV-1 proteins such as transactivator of transcription (Tat) to modulate the CNS immune response, which is primarily mediated by resident glia (microglia, astrocytes) (Hauser et al., 2012; Roy et al., 2011) . Morphine exposure decreased HIV-1-Tat-induced microglial production of pro-inflammatory cytokines TNF-α, IL-6, and CCL2/MCP-1 (Turchan-Cholewo et al., 2009) as well as astrocytic production of IL-8 (Reddy et al., 2012) in vitro. In contrast, morphine significantly increased HIV-1-Tat-induced striatal astrocyte production of TNF-α, IFN-γ, and CCL5/RANTES in vitro (ElHage et al., 2008 (ElHage et al., , 2005 . These effects are likely region-specific: the hippocampus exhibits a more subtle pathology in HIV-Tat transgenic mice than the striatum, including impaired long-term potentiation and reduced dendritic spine density in CA1 pyramidal neurons (Fitting et al., 2013) . There is limited data available on how these morphineinduced alterations in glial cytokine expression affect the overall balance between pro-and anti-inflammatory factors in the virally-infected CNS, and how the effects of morphine on inflammation may vary between regions.
The type 1 IFN response induces potent antiviral defenses to reduce viral replication throughout the periphery and CNS. Within the CNS, type 1 IFN ligands (e.g., IFN-α, IFN-β) are primarily produced by microglia and astrocytes (Schneider et al., 2014; Yao et al., 2010) . High levels of IFN correlated to reduced simian immunodeficiency virus replication in the initial weeks of infection (Barber et al., 2004; Fraietta et al., 2013) and delayed onset of AIDS-like symptoms in the LP-BM5 murine AIDS (MAIDS) model (Heng et al., 1996) . However, both HIV-1 and morphine suppress the type 1 IFN response, thereby accelerating viral replication (Solis et al., 2011; Wang et al., 2012; Wie et al., 2013) .
In our previous work, we observed increased viral load in the
